ArticleAsian Pacific journal of cancer prevention : APJCP2026
Real World Evidence of Clinical Outcomes of First-Line Chemotherapy in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePancreatic cancer has poor prognosis, with a five-year survival rate of approximately 10%. This study evaluated the clinical outcomes of first-line chemotherapy (CMT) for patients with locally advanced and metastatic pancreatic ductal adenocarcinoma (LA/M-PDAC). PATIENTS AND
methodsA retrospective chart review was conducted of patients with LA/M-PDAC who underwent CMT between January 2008 and December 2018. Efficacy data (objective response rate [ORR], disease control rate [DCR], progression-free survival [PFS], and overall survival [OS]) were evaluated and compared using Pearson's chi-squared tests, Kaplan-Meier plots, and log-rank tests.
resultsOf 998 patients diagnosed with LA/M-PDAC, 332 (33.3%) underwent systemic CMT. Among the treatment regimens used, gemcitabine (GEM) was most commonly administered (33.7%). The next most common therapies were (m)FOLFIRINOX and GEM plus capecitabine (GEMCAPE), accounting for 27.4% and 26.2% of cases, respectively. The ORRs were 4.5, 10.3, 23.1, and 19.4% for GEM, GEMCAPE, (m)FOLFIRINOX, and Platinum doublets (PlatD), respectively. Patients who received combination CMTs had significantly longer median PFS than those who received GEM alone (PFS = 4.93 months (mos) for GEMCAPE, 9 mos for (m)FOLFIRINOX, 9.43 mos for PlatD, and 3.87 mos for GEM). However, no significant differences were observed in the median OS rates among the four regimens. The treatment-related grade 3 or 4 adverse events were highest in the (m)FOLFIRINOX group.
conclusionIn the first-line treatment of PDAC, (m)FOLFIRINOX exhibited higher ORR and PFS than GEM or GEMCAPE. However, no survival advantage was observed in the (m)FOLFIRINOX group, suggesting an influence of subsequent therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.